MedTrace Logo

A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above

NCT04510207 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 44101

Last updated 2023-06-18

No results posted yet for this study

Summary

This is a multicenter, randomized, double blind, parallel placebo controlled, phase 3 clinical trial to evaluate the protective efficacy, safety and immunogenicity of inactivated SARS-CoV-2 vaccines in healthy population 18 years old and above.

Conditions

Interventions

BIOLOGICAL

Inactivated SARS-CoV-2 Vaccine (Vero cell)

The inactivated SARS-CoV-2 Vaccine (Vero cell) manufactured by WIBP

BIOLOGICAL

Inactivated SARS-CoV-2 Vaccine (Vero cell)

The inactivated SARS-CoV-2 Vaccine (Vero cell) manufactured by BIBP

BIOLOGICAL

Placebo

The placebo of inactivated SARS-CoV-2 Vaccine (Vero cell) manufactured by WIBP

Sponsors & Collaborators

  • G42 Healthcare company

    collaborator UNKNOWN

  • Abu Dhabi Health Services Company

    collaborator OTHER_GOV

  • Wuhan Institute of Biological Products Co., Ltd

    collaborator INDUSTRY

  • Beijing Institute of Biological Products Co Ltd.

    collaborator INDUSTRY

  • China National Biotec Group Company Limited

    lead INDUSTRY

Principal Investigators

  • Walid A Zaher, MD, MSc,PhD · G42 Healthcare company

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-07-16
Primary Completion
2021-06-16
Completion
2021-12-31

Countries

  • Bahrain
  • Egypt
  • Jordan
  • United Arab Emirates

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04510207 on ClinicalTrials.gov